1 / 5

BEVACIZUMAB |ABEVMY - 100MG/400MG |Apple pharmaceuticals

Abevmy /100mg400mg Injection is an anticancer medicine that is used alone or in combination with other medicines for the treatment of various types of cancers such as colorectal cancer, glioblastoma multiforme, renal cell carcinoma, cervical cancer, ovarian cancer, etc.@ myapplepharma

Emilymia
Télécharger la présentation

BEVACIZUMAB |ABEVMY - 100MG/400MG |Apple pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. BEVACIZUMAB |ABEVMY - 100MG/400MG |Apple pharmaceuticals ABEVMY - 100MG/400MG DESCRIPTION: Category: Monoclonal antibody or Anti-angiogenesis drug Bevacizumab is sold under the brand name Abevmy 100mg/400mg which belongs to vascular endothelial growth factor directed antibody. Abevmy 100mg/400mg consist of human framework regions and murine complementarity-determining regions. Abevmy 100mg/400mg is a combined human monoclonal antibody IgG1, that predicament to and prohibits the biological activity of human vascular endothelial growth factor (VEGF) INDICATION Abevmy 100mg/400mg is indicated for the treatment • In combination with 5-fluorouracil chemotherapy administered intravenously, first or second line drug of choice for Metastatic colon or rectal cancer • Concurrent use with carboplatin and paclitaxel as first line therapy for Non-squamous, non-small cell lung cancer • Used in the treatment of recurrent Glioblastoma in adults • Concurrent use with interferon alfa for Metastatic renal cell cancer • Concurrent use with paclitaxel & cisplatin or paclitaxel & topotecan for Metastatic cervical cancer

  2. • In combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for Epithelial ovarian, fallopian tube or peritoneal cancer ABEVMY - 100MG/400MG DOSAGE Key point: Avoid administrating Abevmy before at least 28 days following surgery and the wound is completely cured Metastatic colorectal carcinoma: The Abevmy usual dosage by concomitant with 5-fluorouracil based chemotherapy. Abevmy 5mg/kg for every 2 weeks IV in concomitant with bolus IFL Abevmy 10mg/kg for every 2 weeks IV in combination with FOLFOX4 Abevmy 5mg/kg IV for every 2 weeks or Abevmy 7.5 mg/kg as IV every 3 weeks by concurrently take with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy Non-small cell lung cancer: The patient’s regular dosage of Abevmy is 15mg/kg IV for every 3 weeks by interacting with carboplatin and paclitaxel

  3. Glioblastoma: Abevmy 10mg/kg administered IV for every 2 weeks Metastatic renal cell cancer: Concurrent use with interferon alfa.: The usual dose of Abevmy is 10mg/kg IV for every 2 weeks Metastatic cervical cancer: The usual dose of Abevmy; Abevmy 15mg/kg given intravenously for every 3 weeks by combining with paclitaxel and cisplatin or with paclitaxel and topotecan Epithelial ovarian, fallopian tube or peritoneal cancer: The usual dose of Abevmy for Platinum opposing: 10mg/kg of Abevmy for every 2 weeks by concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan Or The regular dosage of Abevmy; 15mg/kg of Abevmy given through IV for every 3 weeks by combining with topotecan The usual dose of Abevmy for Platinum responsive; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles The recommended dosage of Abevmy; 15mg/kg of Abevmy given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles. Preparation & administration:Abevmy 100mg/400mg is intravenous solution At initial infusion: given IV infusion over 90 minutes Following infusions: give second infusion over 60 minutes, if tolerated Administer all following infusion over 30minutes Abevmy IV infusion is prepared in aseptic conditionAbevmy 100mg/400mg containing 16ml solution whereas 100mg

  4. containing 4ml Abevmy dilute into 100ml of 0.9% NS Do not dilute with dextrose solution Dispose the remaining drug which is left in a vial under guidance of pharmacist. CONTRAINDICATION No contraindication occurred SIDE EFFECTS Gastrointestinal perforation and fistulae Surgery and wound healing complication Hemorrhage Arterial thromboembolic events Venous thromboembolic events Hypertension Posterior reversible encephalopathy syndrome Renal injury & Proteinuria Infusion reactions Ovarian failure Congestive heart failure Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysesthesia. STORAGE Abevmy 100mg/400mg vial should be stored at 2 to 8℃ (36 to 46℉) Single use vial Discard the left-out medicine under guidance of pharmacist MISSED DOSE

  5. If patient fail to take the dose or missed the cycle means must consult with oncologist and follow the regular dosing schedule Do not take overdose CONTACTS Phone : +91- 9987711567 Email: applepharmaceutical@gmail.com WEBSITE: https://myapplepharma.com/abevmy- 100mg.php https://myapplepharma.com/abevmy- 400mg.php

More Related